CD274 and neoplasm: These include downregulating antigen presentation, which impairs the ability of immune cells to recognize and attack tumor cells, and expression of surface protein ligands, such as Programmed Death-Ligand 1 (PD-L1), that interact with immune checkpoint proteins, such as Programmed Death Protein 1 (PD-1), on immune cells (3).